Peng Xu
- Cancer Research top 5%
- Cancer-related molecular mechanisms research 11
- Cancer, Lipids, and Metabolism 6
- Breast Cancer Treatment Studies 5
- Nephrology top 5%
- Oncology top 5%
- Global Cancer Incidence and Screening 5
-
- Kidney Stones and Urolithiasis Treatments 7
- Ferroptosis and cancer prognosis 5
- Lung Cancer Diagnosis and Treatment 5
-
- RNA modifications and cancer 7
- Cited by
- Cancer ResearchNephrologyOncology
- Partner nations
- ChinaUnited StatesSweden
In The Last Decade
Peng Xu
104 papers receiving 2.3k citations
Hit Papers
Peers
Comparison fields: 5 of 146
- Cancer Research 429
- Nephrology 129
- Oncology 489
- Endocrinology, Diabetes and Metabolism 282
- Health, Toxicology and Mutagenesis 185
Countries citing papers authored by Peng Xu
This map shows the geographic impact of Peng Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peng Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peng Xu more than expected).
Fields of papers citing papers by Peng Xu
This network shows the impact of papers produced by Peng Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peng Xu. The network helps show where Peng Xu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Peng Xu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 0 | |
| 4 | 2024 | 2 | |
| 5 | 2024 | 1 | |
| 6 | 2022 | 8 | |
| 7 | 2022 | 22 | |
| 8 | 2022 | 1 | |
| 9 | 2021 | 12 | |
| 10 | 2021 | 6 | |
| 11 | 2021 | 10 | |
| 12 | 2021 | 11 | |
| 13 | Global, Regional, and National Burden of Diabetes-Related Chronic Kidney Disease From 1990 to 2019breakdown → | 2021 | 193 |
| 14 | Long-Circulating Thermosensitive Liposomes for the Targeted Drug Delivery of Oxaliplatin | 2020 | 1 |
| 15 | Therapeutic Effect of Doxorubicin-Chlorin E6-Loaded Mesoporous Silica Nanoparticles Combined with Ultrasound on Triple-Negative Breast Cancer | 2020 | 1 |
| 16 | 2019 | 6 | |
| 17 | 2019 | 16 | |
| 18 | 2018 | 9 | |
| 19 | [Prevention and treatment of erectile dysfunction after prostatectomy: An update]. | 2017 | 4 |
| 20 | 2016 | 4 |
About Peng Xu
Peng Xu is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 108 papers that have together received 2.3k indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (11 papers), Kidney Stones and Urolithiasis Treatments (7 papers), RNA modifications and cancer (7 papers), Cancer, Lipids, and Metabolism (6 papers), Global Cancer Incidence and Screening (5 papers), Breast Cancer Treatment Studies (5 papers), Ferroptosis and cancer prognosis (5 papers) and Lung Cancer Diagnosis and Treatment (5 papers). The work is most often cited by research in Cancer Research (429 citations), Nephrology (129 citations) and Oncology (489 citations). Peng Xu has collaborated with scholars based in China, United States and Sweden. Frequent co-authors include Zhijun Dai, Yujiao Deng, Zhen Zhai, Yi Zheng, Na Li, Linghui Zhou, Shuai Lin, Kang Liu, Dai Zhang and Jun Lyu.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.